The 16 most recent market catalysts affecting $BNTX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 14, 2026
Corporate Catalyst
Bullish
Impact 85
BioNTech And OncoC4's Gotistobart Shows Hazard Ratio Of 0.56 Versus Docetaxel In PRESERVE-003 Phase 3 Trial For Previously Treated Squamous Non-Small Cell Lung Cancer
The hazard ratio of 0.56 is a very strong indicator of efficacy, suggesting that patients receiving Gotistobart had a 44% lower risk of disease progression or death compared to tho…
Sep 8, 2026
Corporate Catalyst
Bearish
Impact 75
BioNTech shares are trading lower after BMO Capital downgraded the stock from Outperform to Market Perform rating and lowered its price target from $128 to $105.
The downgrade of BioNTech by BMO Capital from 'Outperform' to 'Market Perform' and the significant reduction in its price target from $128 to $105 is a direct negative catalyst for…
Sep 8, 2026
Corporate Catalyst
Bearish
Impact 65
BMO Capital Downgrades BioNTech to Market Perform, Lowers Price Target to $105
BMO Capital's downgrade of BioNTech from Outperform to Market Perform, coupled with a significant reduction in its price target from $128 to $105, signals a less optimistic view fr…
Aug 28, 2026
Corporate Catalyst
Bearish
Impact 85
BioNTech Stock Dips After BNT122-01 Trial Termination
BioNTech's decision to terminate its Phase 2 trial for BNT122-01 is a significant setback for its personalized mRNA cancer treatment pipeline, particularly as it was being tested a…
Aug 28, 2026
Corporate Catalyst
Bearish
Impact 85
BioNTech shaes are trading lower after the company announced it will terminate its Phase 2 BNT122-01 trial.
The termination of a Phase 2 trial for BNT122-01 is a significant negative catalyst for BioNTech, as it represents a failure in a relatively advanced stage of drug development. Thi…
Aug 28, 2026
Corporate Catalyst
Bearish
Impact 85
BioNTech Says It Will Terminate Phase 2 BNT122-01 Trial Of Autogene Cevumeran In ctDNA-Positive Resected Colorectal Cancer After DSMB Identified Numerical Overall Survival Imbalance Between Arms; No New Safety Signals
BioNTech has terminated its Phase 2 trial for BNT122-01, a personalized mRNA cancer vaccine, in colorectal cancer due to a numerical overall survival imbalance. This is a major blo…
Aug 21, 2026
Corporate Catalyst
Bullish
Impact 75
BioNTech shares are trading higher. Yesterday, the company announced it will present clinical data from its diversified development program in lung cancer treatment at the IASLC 2026 World Conference on Lung Cancer.
This headline represents a significant corporate catalyst for BioNTech. The announcement of presenting clinical data, especially in a high-impact area like lung cancer treatment, g…
Aug 20, 2026
Corporate Catalyst
Bullish
Impact 65
BioNTech Will Present New Data From Its Development Program in Lung Cancer Treatment at the IASLC 2026 World Conference on Lung Cancer In September; Data Highlights Progress Across Pumitamig (BNT327/BMS986545) and Gotistobart (BNT316/ONC-392), As Well As BioNTech’s mRNA-Based Immunotherapy Approaches
BioNTech is announcing upcoming presentations at a major medical conference, the IASLC 2026 World Conference on Lung Cancer. This is significant because it indicates progress in th…
Aug 5, 2026
Corporate Catalyst
Bearish
Impact 55
Evercore ISI Group Maintains Outperform on BioNTech, Lowers Price Target to $130
Evercore ISI Group analyst Cory Kasimov maintained an 'Outperform' rating on BioNTech (BNTX) but lowered the price target from $135 to $130. This adjustment signals a slightly redu…
Aug 4, 2026
Corporate Catalyst
Bearish
Impact 85
BNTX stock has given up its prior loss. BioNTech shares were trading lower after the company reported worse-than-expected Q2 financial results and cut its FY26 sales guidance below estimates.
This headline signals a significant corporate catalyst for BioNTech. The combination of poor quarterly performance and a lowered long-term sales outlook directly impacts investor c…
Aug 4, 2026
Corporate Catalyst
Bearish
Impact 92
BioNTech shares are trading lower after the company reported worse-than-expected Q2 financial results and cut its FY26 sales guidance below estimates.
This headline represents a significant corporate catalyst for BioNTech, directly impacting its valuation due to underperforming financials and a lowered future outlook. The cut in …
Aug 4, 2026
Corporate Catalyst
Bearish
Impact 85
BioNTech Lowers FY2026 Sales Guidance from $2.328B-$2.678B to $1.860B-$2.209B vs $2.500B Est
BioNTech's decision to lower its FY2026 sales guidance is a significant event. The revised range of $1.860 billion-$2.209 billion is considerably lower than both the previous guida…
Aug 4, 2026
Corporate Catalyst
Bearish
Impact 95
BioNTech Q2 Adj. EPS $(2.58) Misses $(2.34) Estimate, Sales $122.766M Miss $182.020M Estimate
BioNTech's Q2 earnings report reveals a significant financial underperformance, with adjusted EPS missing estimates by 10.26% and sales missing by 32.55%. This marks a substantial …
Aug 3, 2026
Corporate Catalyst
Neutral
Impact 75
BioNTech Names Orphan Biovitrum's Guido Oelkers As New CEO, Replacing Ugur Sahin
BioNTech has announced a significant leadership change with Guido Oelkers taking over as CEO from Ugur Sahin by early 2027. Oelkers brings extensive experience in the biotechnology…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.